Phosphorylated p68 RNA helicase is overabundant in cancers such as triple-negative breast cancer (TNBC), promoting epthithelial-mesenchymal transformations through β-catenin and up-regulation of Snail1. Capasso and colleagues therefore designed an inhibitor for phosphorylated p68, which they call RX-5902, as a novel strategy to disrup. Wnt-independent β-catenin signaling. The anti-cancer activity of RX-5902 was verified in a range of TNBC cell lines, as well as in animal models derived from cell lines and patients (PDX). Due to its potent activity and previously determined tolerability in a phase I trial at the determined dose of 250 mg, RX-5902 is a promising new approach to treating TNBC patients.
Genomic sequencing of pancreatic ductal adenocarcinoma has begun to identify actionable alterations in patients, most notably in the DNA damage response (DDR) genes. These alterations render the cancer cells sensitive to DNA damaging agents like PARP inhibitors. In this review article, Armstrong and colleagues describe ATM,...
RSS Feeds